Scholarlink

<p>Nanodispersions are dispersed systems that contain particles under 1000&#xa0;nm and are spread throughout the continuous phase. The topical ophthalmic nanodispersions are used to improve the drug permeation across the cornea and to deliver the drug in a sustained manner over an extended period of time. Recent research reported that nanodispersions have the capacity to increase the water solubility of poorly water-soluble drugs. Curcumin and dexamethasone are hydrophobic drugs with poor corneal permeability and bioavailability. The objective of the present study was “to develop and characterize nanodispersions of curcumin with dexamethasone for topical ocular delivery and to evaluate their corneal permeation and anti-angiogenic potential.” The nanodispersions were formulated using polyvinylpyrrolidone K90 and poloxamer 407 at different ratios. The particle size of the developed nanodispersions ranged from 171 ± 0.32 to 184 ± 2.13&#xa0;nm and had a smooth surface with a spherical shape. The transparency and cloud point of the developed nanodispersion showed 90–98% and 66–69&#xa0;°C, respectively. The in-vitro drug release studies showed that 13 to 25% of curcumin and 30 to 97% of dexamethasone were released from nanodispersions within 8&#xa0;h. Furthermore, ex-vivo corneal permeation of developed nanodispersions was evaluated by rabbit cornea. The developed nanodispersions were evaluated by chorioallantoic membrane assay, and it showed better anti-angiogenic potential than pure drug suspension. Hence, the developed nanodispersions have the great potential to enhance ocular bioavailability for the treatment of AMD. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Topical ocular delivery of curcumin with dexamethasone nanodispersions for the treatment of AMD

  • 期刊论文

  • 发表日期：

    2026年7月20日

查看全文
  • Chandrasekar Ponnusamy,
  • Puratchikody Ayarivan,
  • Venkateshwaran Krishnaswami,
  • Subramanian Natesan

摘要

Nanodispersions are dispersed systems that contain particles under 1000 nm and are spread throughout the continuous phase. The topical ophthalmic nanodispersions are used to improve the drug permeation across the cornea and to deliver the drug in a sustained manner over an extended period of time. Recent research reported that nanodispersions have the capacity to increase the water solubility of poorly water-soluble drugs. Curcumin and dexamethasone are hydrophobic drugs with poor corneal permeability and bioavailability. The objective of the present study was “to develop and characterize nanodispersions of curcumin with dexamethasone for topical ocular delivery and to evaluate their corneal permeation and anti-angiogenic potential.” The nanodispersions were formulated using polyvinylpyrrolidone K90 and poloxamer 407 at different ratios. The particle size of the developed nanodispersions ranged from 171 ± 0.32 to 184 ± 2.13 nm and had a smooth surface with a spherical shape. The transparency and cloud point of the developed nanodispersion showed 90–98% and 66–69 °C, respectively. The in-vitro drug release studies showed that 13 to 25% of curcumin and 30 to 97% of dexamethasone were released from nanodispersions within 8 h. Furthermore, ex-vivo corneal permeation of developed nanodispersions was evaluated by rabbit cornea. The developed nanodispersions were evaluated by chorioallantoic membrane assay, and it showed better anti-angiogenic potential than pure drug suspension. Hence, the developed nanodispersions have the great potential to enhance ocular bioavailability for the treatment of AMD.